Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
AVROBIO is a biotechnology business based in the US. AVROBIO shares (AVRO) are listed on the NASDAQ and all prices are listed in US Dollars. AVROBIO employs 122 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $1.19 |
|---|---|
| 52-week range | $0.56 - $1.93 |
| 50-day moving average | $1.18 |
| 200-day moving average | $0.93 |
| Wall St. target price | $3.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.56 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.19 from 2023-03-17
| 1 week (2023-03-13) | -1.65% |
|---|---|
| 1 month (2023-02-17) | -29.59% |
| 3 months (2022-12-20) | 50.63% |
| 6 months (2022-09-20) | 53.93% |
| 1 year (2022-03-16) | N/A |
|---|---|
| 2 years (2021-03-19) | -90.50% |
| 3 years (2020-03-20) | 13.65 |
| 5 years (2018-03-16) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -39.07% |
| Return on equity TTM | -74.8% |
| Profit margin | 0% |
| Book value | $2.24 |
| Market capitalisation | $54.3 million |
TTM: trailing 12 months
We're not expecting AVROBIO to pay a dividend over the next 12 months.
Over the last 12 months, AVROBIO's shares have ranged in value from as little as $0.56 up to $1.93. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AVROBIO's is 1.6286. This would suggest that AVROBIO's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
AVROBIO, Inc. , a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.